EUVIMEDEUVIMED entdecken
Crossref

Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

Seda Kahraman iD, Enes Erul iD, Mustafa Seyyar, Ozge Gumusay, Ertugrul Bayram, Burcin Cakan Demirel, Omer Acar, Sercan Aksoy, Naziyet Kose Baytemur, Elif Sahin, Devrim Cabuk, Gul Basaran und 48 weitere

Future Oncology · 2023

DOI: 10.2217/fon-2022-1287 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Oncology, 2023. Verfasst von Seda Kahraman und 59 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Ankara Yildirim Beyazit University, Ankara City Hospital, Ankara, 06800, Turkey. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer.

Methods

The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansFemaleLetrozoleRetrospective StudiesAminopyridinesTreatment OutcomeAntineoplastic Combined Chemotherapy ProtocolsErb-b2 Receptor Tyrosine KinasesPiperazinesPyridinesPurines

Stichwörter der Autor:innen

CDK 4/6 inhibitorsHER2-negative metastatic breast cancerHR-positiveletrozole

Substanzen

LetrozoleAminopyridinesErb-b2 Receptor Tyrosine KinasespalbociclibPiperazinesPyridinesribociclibPurines

Autor:innen und Institutionen

  • Department of Medical Oncology, Ankara Yildirim Beyazit University, Ankara City Hospital, Ankara, 06800, Turkey.
  • Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, 06590, Turkey.
  • Department of Medical Oncology, Kocaeli University Medical Faculty Hospital, Kocaeli, 41000, Turkey.
  • Department of Medical Oncology, Acibadem University, School of Medicine, Istanbul, 34750, Turkey.
  • Department of Medical Oncology, Cukurova University, Adana, 01330, Turkey.
  • Department of Medical Oncology, Pamukkale University Hospital, Denizli, 20160, Turkey.

ORCID-Profile: Seda Kahraman, Enes Erul, Semra Paydas, Deniz Can Guven, Mutlu Hizal, Erkan Kayikcioglu, Eda Eylemer Mocan, Cihan Erol, Ali Alkan, Berna Bozkurt Duman

Zitieren

APA

Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., Acar, O., Aksoy, S., Baytemur, N. K., Sahin, E., Cabuk, D., Basaran, G., Paydas, S., Yaren, A., Guven, D. C., Erdogan, A. P., Demirci, U., Yasar, A., Bayoglu, İ. V., …, & Aykan, M. B. (2023). Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer. Future Oncology. https://doi.org/10.2217/fon-2022-1287

Vancouver

Kahraman S, Erul E, Seyyar M, Gumusay O, Bayram E, Demirel BC, et al. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer. Future Oncology. 2023. doi:10.2217/fon-2022-1287

BibTeX
@article{Kahraman2023,
  author = {Kahraman, Seda and Erul, Enes and Seyyar, Mustafa and Gumusay, Ozge and Bayram, Ertugrul and Demirel, Burcin Cakan and Acar, Omer and Aksoy, Sercan and Baytemur, Naziyet Kose and Sahin, Elif and Cabuk, Devrim and Basaran, Gul and Paydas, Semra and Yaren, Arzu and Guven, Deniz Can and Erdogan, Atike Pinar and Demirci, Umut and Yasar, Alper and Bayoglu, İbrahim Vedat and Hizal, Mutlu and Gulbagci, Burcu and Paksoy, Nail and Davarci, Sena Ece and Yilmaz, Funda and Dogan, Ozlem and Orhan, Sibel Oyucu and Kayikcioglu, Erkan and Aytac, Ali and Keskinkilic, Merve and Mocan, Eda Eylemer and Unal, Olcun Umit and Aydin, Esra and Yucel, Hakan and Isik, Deniz and Eren, Onder and Uluc, Basak Oyan and Ozcelik, Melike and Hacibekiroglu, Ilhan and Aydiner, Adnan and Demir, Hacer and Oksuzoglu, Berna and Cilbir, Ebru and Cubukcu, Erdem and Cetin, Bulent and Oktay, Esin and Erol, Cihan and Okutur, Sadi Kerem and Yildirim, Nilgun and Alkan, Ali and Selcukbiricik, Fatih and Aksoy, Asude and Karakas, Yusuf and Ozkanli, Gulhan and Duman, Berna Bozkurt and Aydin, Dincer and Dulgar, Ozgecan and Er, Muhammed Muhiddin and Teker, Fatih and Yavuzsen, Tugba and Aykan, Musa Baris},
  title = {Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer},
  journal = {Future Oncology},
  year = {2023},
  doi = {10.2217/fon-2022-1287}
}
Kostenlos starten →